Neuroblastoma (NB) is the most common solid tumor in childhood. Twenty percent of patients display MYCN amplification, which indicates a very poor prognosis. MYCN is a highly specific target for an NB tumor therapy as MYCN expression is absent or very low in most normal cells, while, as a transcription factor, it regulates many essential cell activities in tumor cells. We aim to develop a therapy for NB based on MYCN silencing by short interfering RNA (siRNA) molecules, which can silence target genes by RNA interference (RNAi), a naturally occurring method of gene silencing. It has been shown previously that MYCN silencing can induce apoptosis and differentiation in MYCN amplified NB. In this article, we have demonstrated that siRNA-mediated silencing of MYCN in MYCN-amplified NB cells induced neurogenesis in NB cells, whereas retinoic acid (RA) treatment did not. RA can differentiate NB cells and is used for treatment of residual disease after surgery or chemotherapy, but resistance can develop. In addition, MYCN siRNA treatment suppressed growth in a MYCN-amplified NB cell line more than that by RA. Our result suggests that gene therapy using RNAi targeting MYCN can be a novel therapy toward MYCN-amplified NB that have complete or partial resistance toward RA.
Get full access to this article
View all access options for this article.
References
1.
HuangM and Weiss.WA (2013). Neuroblastoma and MYCN. Cold Spring Harb Perspect Med, 3:a014415.
2.
KangJH, RychahouPG, IsholaTA, QiaoJ, EversBM and ChungDH. (2006). MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun, 351:192–197.
3.
BuechnerJ and EinvikC. (2012). N-myc and noncoding RNAs in neuroblastoma. Mol Cancer Res, 10:1243–1253.
4.
PichlerM and Calin.GA (2014). Long noncoding RNA in neuroblastoma: new light on the (old) N-Myc story. J Natl Cancer Inst, 106:dju150.
5.
MarisJM, HogartyMD, BagatellR and CohnSL. (2007). Neuroblastoma. Lancet, 369:2106–2120.
6.
MurphyJM and La QuagliaMP. (2014). Advances in the surgical treatment of neuroblastoma: a review. Eur J Pediatr Surg, 24:450–456.
7.
CheungNK and DyerMA. (2013). Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer, 13:397–411.
8.
DzieranJ, Rodriguez GarciaA, WestermarkUK, HenleyAB, Eyre SanchezE, TragerC, JohanssonHJ, LehtioJ and Arsenian-HenrikssonM. (2018). MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling. Proc Natl Acad Sci U S A, 115:E1229–E1238.
9.
ClarkO, DagaS and StokerAW. (2013). Tyrosine phosphatase inhibitors combined with retinoic acid can enhance differentiation of neuroblastoma cells and trigger ERK- and AKT-dependent, p53-independent senescence. Cancer Lett, 328:44–54.
10.
YuM, OhiraM, LiY, NiizumaH, OoML, ZhuY, OzakiT, IsogaiE, NakamuraY, et al. (2009). High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol, 34:931–938.
11.
BaroneG, AndersonJ, PearsonAD, PetrieK and CheslerL. (2013). New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK. Clin Cancer Res, 19:5814–5821.
12.
PloesslC, PanA, MaplesKT and LoweDK. (2016). Dinutuximab: an anti-GD2 monoclonal antibody for high-risk neuroblastoma. Ann Pharmacother, 50:416–422.
13.
WestermarkUK, WilhelmM, FrenzelA and HenrikssonMA. (2011). The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol, 21:256–266.
14.
BeltranH. (2014). The N-myc oncogene: maximizing its targets, regulation, and therapeutic potential. Mol Cancer Res, 12:815–822.
15.
DuffyDJ, KrsticA, HalaszM, SchwarzlT, FeyD, IljinK, MehtaJP, KillickK, WhildeJ, et al. (2015). Integrative OMICS reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget, 6:43182–43201.
16.
SaboA, KressTR, PelizzolaM, de PretisS, GorskiMM, TesiA, MorelliMJ, BoraP, DoniM, et al. (2014). Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature, 511:488–492.
17.
WalzS, LorenzinF, MortonJ, WieseKE, von EyssB, HeroldS, RycakL, Dumay-OdelotH, KarimS, et al. (2014). Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature, 511:483–487.
18.
HeS, LiuZ, OhDY and Thiele.CJ (2013). MYCN and the epigenome. Front Oncol, 3:1.
19.
ZimmermanKA, YancopoulosGD, CollumRG, SmithRK, KohlNE, DenisKA, NauMM, WitteON, Toran-AllerandD, et al. (1986). Differential expression of myc family genes during murine development. Nature, 319:780–783.
20.
ZhuQ, FengC, LiaoW, ZhangY and Tang.S (2013). Target delivery of MYCN siRNA by folate-nanoliposomes delivery system in a metastatic neuroblastoma model. Cancer Cell Int, 13:65.
21.
FengC, WangTY, TangRH, WangJW, LongH, GaoXN and TangSQ. (2010). Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int, 26:1185–1191.
22.
NaraK, KusafukaT, YonedaA, OueT, SangkhathatS and FukuzawaM. (2007). Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol, 30:1189–1196.
23.
BurkhartCA, ChengAJ, MadafiglioJ, KavallarisM, MiliM, MarshallGM, WeissWA, KhachigianLM, NorrisMD and HaberM. (2003). Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. J Natl Cancer Inst, 95:1394–1403.
24.
FireA, XuS, MontgomeryMK, KostasSA, DriverSE and MelloCC. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391:806–811.
25.
AdamsD, Gonzalez-DuarteA, O'RiordanWD, YangCC, UedaM, KristenAV, TournevI, SchmidtHH, CoelhoT, et al. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med, 379:11–21.
26.
LeiY, TangL, XieY, XianyuY, ZhangL, WangP, HamadaY, JiangK, ZhengW and Jiang.X (2017). Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. Nat Commun, 8:15130.
27.
ZhouJ, WuY, WangC, ChengQ, HanS, WangX, ZhangJ, DengL, ZhaoD, et al. (2016). pH-sensitive nanomicelles for high-efficiency siRNA delivery in vitro and in vivo: an insight into the design of polycations with robust cytosolic release. Nano Lett, 16:6916–6923.
28.
ChakrabortyC, SharmaAR, SharmaG, DossCGP and LeeSS. (2017). Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids, 8:132–143.
29.
GrosseSM, TagalakisAD, MustapaMF, ElbsM, MengQH, MohammadiA, TaborAB, HailesHC and HartSL. (2010). Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. FASEB J, 24:2301–2313.
30.
TagalakisAD, GrosseSM, MengQH, MustapaMF, KwokA, SalehiSE, TaborAB, HailesHC and HartSL. (2011). Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. Biomaterials, 32:1370–1376.
31.
TagalakisAD, HeL, SaraivaL, GustafssonKT and HartSL. (2011). Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials, 32:6302–6315.
TagalakisAD, SaraivaL, McCarthyD, GustafssonKT and HartSL. (2013). Comparison of nanocomplexes with branched and linear peptides for siRNA delivery. Biomacromolecules, 14:761–770.
KaplanDR, HempsteadBL, Martin-ZancaD, ChaoMV and ParadaLF. (1991). The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science, 252:554–558.
36.
ArmstrongJL, TaylorGA, ThomasHD, BoddyAV, RedfernCP and VealGJ. (2007). Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer, 96:1675–1683.
37.
HammerleB, YanezY, PalancaS, CaneteA, BurksDJ, CastelV and Font de MoraJ. (2013). Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor. PLoS One, 8:e76761.
38.
ReynoldsCP, MatthayKK, VillablancaJG and MaurerBJ. (2003). Retinoid therapy of high-risk neuroblastoma. Cancer Lett, 197:185–192.
39.
VealGJ, ColeM, ErringtonJ, PearsonAD, FootAB, WhymanG, Boddy; AV, GroupUPW. (2007). Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma—a study of the United Kingdom Children's Cancer Study Group. Br J Cancer, 96:424–431.
40.
DobrotkovaV, ChlapekP, MazanekP, SterbaJ and Veselska.R (2018). Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. BMC Cancer, 18:1059.
41.
IraciN, DiolaitiD, PapaA, PorroA, ValliE, GherardiS, HeroldS, EilersM, BernardoniR, Della ValleG and PeriniG. (2011). A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res, 71:404–412.
42.
EggertA, GrotzerMA, ZuzakTJ, WiewrodtBR, HoR, IkegakiN and BrodeurGM. (2001). Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res, 61:1314–1319.
43.
PetersonS and BogenmannE. (2004). The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation. Oncogene, 23:213–225.
44.
DuffyDJ, KrsticA, HalaszM, SchwarzlT, KonietznyA, IljinK, HigginsDG and Kolch.W (2017). Retinoic acid and TGF-beta signalling cooperate to overcome MYCN-induced retinoid resistance. Genome Med, 9:15.
45.
SzemesM, GreenhoughA and Malik.K (2019). Wnt signaling is a major determinant of neuroblastoma cell lineages. Front Mol Neurosci, 12:90.
46.
WangY, GaoS, WangW, XiaY and LiangJ. (2018). Downregulation of NMyc inhibits neuroblastoma cell growth via the Wnt/betacatenin signaling pathway. Mol Med Rep, 18:377–384.
47.
BeckerJ and WiltingJ. (2018). WNT signaling, the development of the sympathoadrenal-paraganglionic system and neuroblastoma. Cell Mol Life Sci, 75:1057–1070.
48.
DuffyDJ, KrsticA, SchwarzlT, HalaszM, IljinK, FeyD, HaleyB, WhildeJ, Haapa-PaananenS, et al. (2016). Wnt signalling is a bi-directional vulnerability of cancer cells. Oncotarget, 7:60310–60331.
49.
JoshiS, GuleriaRS, PanJ, DipetteD and SinghUS. (2007). Heterogeneity in retinoic acid signaling in neuroblastomas: role of matrix metalloproteinases in retinoic acid-induced differentiation. Biochim Biophys Acta, 1772:1093–1102.
50.
ChlapekP, SlavikovaV, MazanekP, SterbaJ and Veselska.R (2018). Why differentiation therapy sometimes fails: molecular mechanisms of resistance to retinoids. Int J Mol Sci, 19. DOI: 10.3390/ijms19010132.
51.
StevisonF, JingJ, TripathyS and IsoherranenN. (2015). Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer. Adv Pharmacol, 74:373–412.
52.
TweddleDA, MalcolmAJ, BownN, PearsonAD and LunecJ. (2001). Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res, 61:8–13.
53.
KeshelavaN, SeegerRC, GroshenS and ReynoldsCP. (1998). Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res, 58:5396–5405.
54.
EdsjoA, NilssonH, VandesompeleJ, KarlssonJ, PattynF, CulpLA, SpelemanF and PahlmanS. (2004). Neuroblastoma cells with overexpressed MYCN retain their capacity to undergo neuronal differentiation. Lab Invest, 84:406–417.
55.
GuglielmiL, CinnellaC, NardellaM, MarescaG, ValentiniA, MercantiD, FelsaniA and D'AgnanoI. (2014). MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells. Cell Death Dis, 5:e1081.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
